---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic impact on families"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Economic impact on families. Topics: Direct non-medical and indirect costs borne by patients and families in the United Kingdom; Caregiver burden and changes in employment; Health insurance, Medicaid waivers, and access burden in a U.S. survey; Out-of-pocket costs and financial assistance in a U.S. survey; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Niemann-Pick disease type C on Families

<a id="topic-2.2.1.8.3-1"></a>

### Direct non-medical and indirect costs borne by patients and families in the United Kingdom

> “Direct non-medical costs accounted for 24% of the average annual cost per patient, mainly due to specialist education, and indirect costs 30%.”
> “As demonstrated by this study, a substantial proportion of the cost is shifted from the healthcare system to the patient, family and non-medical providers.”

Source: [Imrie et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19725798/)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver burden and changes in employment

> “Along with these impacts, there was an increased risk of experiencing dangerous or life-threatening situations leading to loss of patient independence and additional caregiver burden, often requiring changes in lifestyle such as giving up work.”
> “Of the 43 caregivers completing the survey, 40 were a parent of the patient, one sibling, one grandparent, and one aunt.”

Source: [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)

<a id="topic-2.2.1.8.3-3"></a>

### Health insurance, Medicaid waivers, and access burden in a U.S. survey

> “Of the 79 respondents who completed the survey, 67 participated in interviews.”
> “However, 61% of respondents were unaware of Medicaid waivers and did not avail of them.”
> “Overall, 50% of respondents with childhood onset NPC selected Medicaid/Medicare and private insurance; 35% utilized Medicaid waivers.”
> “The most frequently cited access burden was the process of obtaining medical care and services.”
> “Delays and denials in obtaining essential medication, equipment, and services contributed to disease progression.”
> “Caregivers faced burnout and often questioned the utility of their advocacy.”

Source: [Diaz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9438239/)

<a id="topic-2.2.1.8.3-4"></a>

### Out-of-pocket costs and financial assistance in a U.S. survey

> “Most respondents (90%) did not have difficulty paying for their medical expenses; however, this may reflect lack of approved therapy or bias in the group that was studied.”
> “Often, respondents mentioned paying high co-pays for drugs, especially miglustat, which is used off-label and costs approximately $58,000 per month and may not be covered by waivers”
> “Most respondents did not use a health savings account (68%) or seek financial assistance from co-pay support programs (92%), reduced payment programs (97%), free drug programs (95%), or nonprofit organizations (94%).”

Source: [Diaz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9438239/)

<a id="topic-2.2.1.8.3-5"></a>

### Out-of-pocket exposure for approved therapies under Medicare Part B

> “If billed under Part B, Medicare recipients are usually responsible for 20% of the cost”
> “However, this is likely not the only reason, as 100% of patients with Medicaid had $0 out-of-pocket costs but still around 20% of prescription claims to Medicaid were reversed.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

<a id="topic-2.2.1.8.3-6"></a>

### Family and carer burden in the Australian standard of care

> “A formal diagnosis, once established, places a substantial burden on the whole family, the negative impact of which is far‐reaching.”
> “Effective and optimal patient outcomes necessitate access to specialist multidisciplinary team (MDT) care, placing considerable societal, administrative and financial burden on the individual diagnosed with NP‐C, their family and carers.”
> “The burden of care coordination places significant strain on the carer.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.8.3-7"></a>

### Public education and disability services for affected children in the United States

> “Developmental Disabilities Administration (DDA) enrollment is recommended.”
> “DDA is a US public agency that provides services and support to qualified individuals.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
